Fig. 3From: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysisRecurrence patterns among retrospective stage III cohort stratified by vaccine versus no adjuvant therapy (left, p = 0.5) indicating the number of patients with resectable versus non-resectable recurrences, and specific sites of disease recurrence among the stage III adjuvant NY-ESO1 vaccine cohort (right, n = 35)Back to article page